FDA-approved subcutaneous infliximab ZYMFENTRA™ shows long-term efficacy and safety in treating Crohn's disease and ulcerative colitis, supporting its use as a maintenance treatment.

ZYMFENTRA™ (infliximab-dyyb), the first FDA-approved subcutaneous infliximab, has demonstrated long-term efficacy and safety in treating adults with moderately to severely active Crohn's disease and ulcerative colitis over two years, according to findings from the extended LIBERTY studies and a post-hoc analysis. The results support ZYMFENTRA™ as a maintenance treatment option for these conditions.